XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Description of Business and Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 3 Months Ended
Jan. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
Apr. 30, 2021
USD ($)
Mar. 31, 2023
USD ($)
Segment
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Jul. 01, 2013
USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Accumulated deficit       $ (3,227,264,000)   $ (3,217,469,000)    
Cash and cash equivalents       85,869,000   69,767,000    
Short-term investments       80,273,000   101,079,000    
Long-term investments       492,000   1,961,000    
Financing liability       $ 104,000,000.0   104,100,000    
Number of operating segment | Segment       1        
Purchase of available-for-sale investment         $ 5,000,000      
Maximum | AFREZZA product sales                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Sales return right following product expiration in months       12 months        
Minimum | AFREZZA product sales                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Sales return right following product expiration in months       6 months        
Convertible Promissory Note | Thirona Bio, Inc.                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Purchase of available-for-sale investment $ 5,000,000.0 $ 3,000,000.0            
Interest rate       6.00%        
MidCap Credit Facility                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Principal amount [1]       $ 40,000,000.0   $ 40,000,000.0    
Principal prepayment against outstanding term loans     $ 10,000,000.0          
MidCap Credit Facility | Tranche Three                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Amount available under credit facility     $ 60,000,000.0 60,000,000.0     $ 25,000,000.0  
Milestone Rights Liability | Deerfield                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Contingent liability remain payable       $ 60,000,000.0       $ 60,000,000.0
Milestone Rights Liability | Maximum | Deerfield                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Contingent liability for milestone payments               $ 90,000,000.0
[1] In August 2022, the Company amended the MidCap credit facility and transitioned the benchmark interest rate from LIBOR to the Secured Overnight Financing Rate (“SOFR”). The interest rate prior to the amendment was one-month LIBOR (1% floor) plus 6.25% (capped at a total of 8.25%).